Familial and hormonal risk factors for papillary serous uterine cancer

Objectives: To identify genetic and non-genetic risk factors for papillary serous uterine cancer.

Methods: A case-control study was conducted. Case women with papillary serous uterine cancer were compared with two control groups: 1) women with endometrioid uterine cancer and 2) healthy women with no past history of cancer. Cases and controls were matched for age (within two years) and ethnic group. All study subjects completed a questionnaire addressing family history. The cases and healthy controls were assessed for factors associated with estrogen exposure.

Results: The risks of breast cancer (RR 1.84, CI 1.03-3.31) and of prostate cancer (RR 2.21, CI 0.77-6.37) were higher among the relatives of patients with papillary serous uterine cancer, than among relatives of those with endometrioid uterine cancer. Other significant risk factors included weight at 18 years (p = 0.04) and the use of estrogen replacement therapy (p = 0.04).

Conclusion: Relatives of women with papillary serous cancer of the uterus had an increased risk of breast and prostate cancer. Hormonal exposure also increases the risk for this cancer. These findings suggest that predisposing genetic factors, possibly related to hormone metabolism, may be common to the three forms of cancer.

Hormonal risk factors; Papillary serous uterine cancer

[1] Magri pies U., Naftolin F., Schwatrz P. E., Carcangiu M. L.: "Highgrade endometrial carcinoma in tarnoxifen-treated breast cancer patients". J. Clin. Oncol., 1993, 11, 485.

[2] Silva E. G., Tornos C., Malpica A., Mitchell M. F.:''Uterine neoplasrns in patients treated with tamoxifen". J. Cellular Biochern., 1995, 23, 179.

[3] Moslehi R., Chu W., Karlan B. Y., Fishman D. A., Risch H., Fields A. L. A. et al.:'·BRCA 1 and BRCA2 analy、is of 208 A、hkenazi Jewish women with ovarian cancer". Arn. J. Hurn. Genet. (in press)

[4] Aziz S. Kuperstein G. Rosen 13. McLaughlin J, Narod S A genetic epiderniologic study of fallopian tube cancer. Gynecol Oncol. in press.

[5] Kaplan E. J., Caputo T. A., Shen P. U. F.. Sassoon R. L Soslow R A.: "Familial papillary serous carcinoma of the cervix, peritoneum, and ovary: a report of the first case". Gynecol. On col., 1998, 70, 289.

[6] Hornreich G., Beller U., Lavie 0., Renbaurn.P, Cohen Y., LevyLahad E.: "Is uterine pap仆lary carcinoma a BRCA L-related disease? Case report and review of the literature". Gynecol. Oncol., 1999, 75, 300.

[7] Go、hen R.. Chu W.. Elit L., Pal T., Hakiirni J., Ackerman I. et al: ''ls uterine papillary serous adenocarcinoma a manifestation of the Hereditary Breast-Ovarian Cancer Syndrome". Gynecl. Oncol., 2000, 79, 477.

[8] Sherrna'n M. E., Sturgeon S.. Brinton L. A.. Potischman N .. Kurman R. J., Berman M. L. et al.: "Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas". Mod. Pathol.. 1997, 10, 963.

[9] Gruber S. B., Thompson W. D.: "A population-based study of endometrial cancer and familial risk in younger women". Cancer Epidemiol., Biornark. and Preven., 1996, 5, 411.

[10] Parazinni F..La Vecchia C.、Moroni S.. Chatenoud L., Ricci E.: "F amily history and the risk of endometrial cancer". Int. J. Cancer, 1994, 59, 460.

[11] Bergman L., Beelen M. L. R., Gallee M. P. W., Hollema H.. Benraadt J., van Leeuwen F. E., ALERT Group: "Risk and prognosis of endometrial cancer after tamoxifen for breast cancer". Lancet, 2000, 356, 881.

[12] Narod S. A., Pal T., Graham T., Mitchell M.: "Fyles a letter to the editor: Tamoxifen and risk of endometrial cancer". Lancet, 2001. 357, 65.